# Targeted AntiBiotics for Chronic Pulmonary Diseases

> **NCT03262142** · PHASE4 · TERMINATED · sponsor: **Chronic Obstructive Pulmonary Disease Trial Network, Denmark** · enrollment: 51 (actual)

## Conditions studied

- COPD
- Respiratory Tract Infections
- Pseudomonas Aeruginosa
- Bronchiectasis
- Asthma

## Interventions

- **DRUG:** Piperacillin/tazobactam
- **DRUG:** Ciprofloxacin

## Key facts

- **NCT ID:** NCT03262142
- **Lead sponsor:** Chronic Obstructive Pulmonary Disease Trial Network, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-10
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2023-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03262142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03262142, "Targeted AntiBiotics for Chronic Pulmonary Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03262142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*